

Contents

| | |
|---|------------|
| Preface | iii |
| 1. Introduction | 1 |
| 1.1 History of Bioavailability Studies | 1 |
| 1.2 Formulations and Routes of Administration | 4 |
| 1.3 Pharmacokinetic Parameters | 5 |
| 1.4 Clinically Important Differences | 11 |
| 1.5 Assessment of Bioequivalence | 12 |
| 1.6 Decision Rules and Regulatory Aspects | 14 |
| 1.7 Statistical Considerations | 17 |
| 1.8 Aims and Structure of the Book | 21 |
| 2. Designs of Bioavailability Studies | 23 |
| 2.1 Introduction | 23 |
| 2.2 The Study Objective | 24 |
| 2.3 Basic Design Considerations | 26 |
| 2.4 The Parallel Design | 28 |
| 2.5 The Crossover Design | 29 |
| 2.6 The Balanced Incomplete Block Design | 43 |
| 2.7 The Selection of Design | 46 |
| | vii |

| | |
|---|------------|
| 3. Statistical Inferences for Effects from a Standard 2 × 2 Crossover Design | 48 |
| 3.1 Introduction | 48 |
| 3.2 The Carry-Over Effects | 50 |
| 3.3 The Direct Drug Effect | 52 |
| 3.4 The Period Effect | 56 |
| 3.5 The Analysis of Variance | 59 |
| 3.6 An Example | 63 |
| 4. Statistical Methods for Average Bioavailability | 70 |
| 4.1 Introduction | 70 |
| 4.2 The Confidence Interval Approach | 72 |
| 4.3 The Methods of Interval Hypotheses Testing | 88 |
| 4.4 Bayesian Methods | 93 |
| 4.5 Nonparametric Methods | 109 |
| 4.6 Discussion and Other Alternatives | 119 |
| 5. Power and Sample Size Determination | 126 |
| 5.1 Introduction | 126 |
| 5.2 Hypotheses and Type I and Type II Errors | 127 |
| 5.3 Power and Relative Efficiency | 134 |
| 5.4 Sample Size Determination | 154 |
| 6. Transformation and Analysis of Individual Subject Ratios | 162 |
| 6.1 Introduction | 162 |
| 6.2 Multiplicative (or Log-Transformed) Model | 163 |
| 6.3 Bioequivalence Measures | 164 |
| 6.4 Maximum Likelihood Estimator | 166 |
| 6.5 Minimum Variance Unbiased Estimator | 168 |
| 6.6 Mean of Individual Subject Ratios | 169 |
| 6.7 Ratio of Formulation Means | 172 |
| 6.8 Comparison of MLE, MVUE, MIR, and RM | 175 |
| 6.9 An Example | 180 |
| 6.10 Discussion | 184 |
| 7. The Assessment of Inter- and Intra-Subject Variabilities | 186 |
| 7.1 Introduction | 186 |
| 7.2 Variability and Decision-Making | 187 |
| 7.3 Point and Interval Estimates | 189 |

| | | |
|------------|---|------------|
| 7.4 | Tests for Equality of Variabilities | 195 |
| 7.5 | Equivalence in Variability of Bioavailability | 204 |
| 7.6 | CV Assessment | 211 |
| 7.7 | Discussion | 214 |
| 8. | Assumptions and Outliers Detection | 217 |
| 8.1 | Introduction | 217 |
| 8.2 | Tests for Assumptions | 218 |
| 8.3 | The Definition of Outlying Observations | 231 |
| 8.4 | Detection of Outlying Subjects | 235 |
| 8.5 | Detection of Outlying Observations | 245 |
| 8.6 | Discussion | 251 |
| 9. | Optimal Crossover Designs for Two Formulations | 253 |
| 9.1 | Introduction | 253 |
| 9.2 | Balaam's Design | 254 |
| 9.3 | The Two-Sequence Dual Design | 263 |
| 9.4 | Optimal Four-Period Designs | 272 |
| 9.5 | Transformation and Individual Subject Ratios | 284 |
| 9.6 | Discussion | 286 |
| 10. | Assessment of Bioequivalence for More than Two Formulations | 289 |
| 10.1 | Introduction | 289 |
| 10.2 | Assessment of Average Bioavailability with More than Two Formulations | 290 |
| 10.3 | Analysis for Williams Designs | 295 |
| 10.4 | Analysis for Balanced Incomplete Block Design | 308 |
| 10.5 | Discussion | 311 |
| 11. | Assessment of Bioequivalence for Drugs with Negligible Plasma Levels | 317 |
| 11.1 | Introduction | 317 |
| 11.2 | Design and Clinical Endpoints | 317 |
| 11.3 | Statistical Considerations | 319 |
| 11.4 | Weighted Least Squares Method | 324 |
| 11.5 | Log-Linear Models | 331 |
| 11.6 | Generalized Estimating Equations (GEEs) | 335 |
| 11.7 | Analysis of Time to Onset of a Therapeutic Response | 338 |
| 11.8 | Discussion | 341 |

| | |
|--|------------|
| 12. Some Related Problems in Bioavailability Studies | 343 |
| 12.1 Introduction | 343 |
| 12.2 Drug Interaction Study | 344 |
| 12.3 Dose Proportionality Study | 349 |
| 12.4 Steady State Analysis | 356 |
| 12.5 Population Pharmacokinetics | 359 |
| References | 361 |
| Appendix A: Statistical Tables | 371 |
| Appendix A.1 Areas of Upper Tail of the Standard Normal Distribution | 373 |
| Appendix A.2 Upper Quantiles of a χ^2 Distribution | 374 |
| Appendix A.3 Upper Quantiles of a Central t Distribution | 376 |
| Appendix A.4 Upper Quantiles of an F Distribution | 377 |
| Appendix A.5 Upper Quantiles of the Distribution of Wilcoxon-Mann-Whitney Statistic | 385 |
| Appendix B: SAS Programs | 391 |
| Appendix B.1 Procedures for Average Bioavailability | 393 |
| Appendix B.2 Bayesian Method by Grieve | 402 |
| Appendix B.3 MVUE, MLE, RI, MIR for a 2×2 Crossover Design | 404 |
| Appendix B.4 Parametric and Nonparametric Versions of Pitman-Morgan Test | 407 |
| Index | 411 |